Program 2: Cancer Imaging Program (CIP)

项目概要/摘要：癌症成像计划（CIP） 癌症成像计划（CIP）的科学目标是开发和应用成像技术， 用于癌症预防和干预研究的成像方法。CIP的成员正在 该领域的最前沿，并在利用成像的理论基础方面取得了显著成功 科学，以推进新的成像技术，为广泛的关键癌症应用。方案活动 主题1）主要生物医学成像技术的发展 主题2）分子成像和先进造影剂的开发，包括分析 主题3）与癌症相关的理论影像科学的进展。了CIP 提供了一个动态的以癌症为重点的环境，促进了项目间的合作， 翻译管道，促进研究申请进入制药商发起的临床试验（IIT）。 CIP有两个具体目标：目标1）促进成像科学和技术的进步， 在癌症生物学、早期癌症检测、癌症发展和监测方面的应用 目的2）促进科学转化为临床试验， 通过制药商发起的临床试验（IIT）在临床上开发和测试新技术， 在其他临床研究中心协调验证。CIP领导，与UACC和University of 亚利桑那州（UA）的领导层，在确保原型测试/开发的试点资金来源方面发挥了重要作用 并提供独特的实验室和临床方法，以帮助研究人员参与 发现和开发新的诊断方法和新的抗癌疗法。CIP建立在 美国大学在成像科学方面的卓越成就。总督察有31名成员，来自10个不同的部门， 互补的，专业的技能来自多个学院和部门在整个UA。联合 在多个部门的任命和研究生跨学科计划的成员提供了 高度创新研究所需的动态互动网络。有效整合不同的 癌症成像研究的会员资格，结合资助的指导和培训计划， 导致癌症诊断/治疗新方法的持续、广泛发展， 重要的高影响力贡献。CIP成员为249份癌症相关手稿做出了贡献， 其中33%是项目内的，31%是项目间的。截至2015年9月1日，CIP 该计划获得了超过750万美元的年度赠款，其中300万美元来自NCI，400万美元来自 其他同行评审资金。计划成员持有的主要资金包括中心赠款 （P41 EB 002035），支持UA的“伽马射线成像中心”和培训补助金（T32 EB 000809） 题为“生物医学成像和光谱学”

Project Summary / Abstract: Cancer Imaging Program (CIP) The scientific goal of the Cancer Imaging Program (CIP) is to develop and apply imaging technologies and imaging methods for cancer prevention and intervention studies. Members of the CIP are working at the forefront of the field and have been eminently successful in utilizing the theoretical underpinnings of imaging science to advance new imaging technologies for a wide array of critical cancer applications. Program activities are organized under three major themes: Theme 1) Advancement of major biomedical imaging technologies for cancer; Theme 2) Molecular imaging and the development of advanced contrast agents, including analysis of their mechanisms; and Theme 3) Advancement of theoretical image science related to cancer. The CIP provides a dynamic cancer-focused environment that fosters inter-programmatic collaborations with a robust translational pipeline that facilitates entry of research applications into investigator-initiated clinical trials (IITs). CIP has two Specific Aims: Aim 1) To promote advances in imaging science and technology and their application in the context of cancer biology, early cancer detection, development and monitoring of cancer therapies, and cancer prevention studies; Aim 2) To promote translation of the science into clinical trials and development and testing of new technologies in the clinic through investigator-initiated clinical trials (IITs) and coordinated validation at other clinical sites. CIP leadership, in cooperation with the UACC and University of Arizona (UA) leadership, is instrumental in securing sources for pilot funding for prototype testing/development and in providing access to unique laboratory and clinical methodologies to aid researchers who are involved in the discovery and development of new diagnostic methods and new anticancer therapies. The CIP builds on the UA's excellence in imaging science. The CIP has 31 Members, from 10 different departments, with complementary, specialized skills drawn from multiple colleges and departments across the UA. Joint appointments in multiple departments and membership in Graduate Interdisciplinary Programs provide the dynamic networks of interaction required for highly innovative research. The effective integration of the diverse Membership into cancer imaging research, combined with funded mentoring and training programs, have resulted in the sustained, broad-based development of novel approaches to cancer diagnosis/therapy and significant high-impact contributions. CIP Members have contributed to 249 cancer-relevant manuscripts, of which 33% were intra-programmatic and 31% were inter-programmatic. As of September 1, 2015, the CIP Program secured more than $7.5M in total annual grant dollars, with $3M of that from the NCI and $4M in other peer-reviewed funding. Major funding held by Program Members includes a Center Grant (P41EB002035) that supports UA's “Center for Gamma Ray Imaging” and a Training grant (T32EB000809) entitled “Biomedical Imaging and Spectroscopy.”